Compliance Rate

Compliance Rate 60.0%
Compliant submissions 60
Incompliant submissions 40
Total trials 100

Your Clinical Trials

Showing 25 of 100 entries
View as:

Study 10

Phase: N/A Priority: Normal
NCT ID: NCT00000009 Org: User:
Start: 01/11/22 End: 01/13/22 Due: 01/14/22

Study 20

Phase: N/A Priority: Normal
NCT ID: NCT00000019 Org: User:
Start: 01/21/22 End: 01/23/22 Due: 01/24/22

Study 30

Phase: N/A Priority: Normal
NCT ID: NCT00000029 Org: User:
Start: 01/31/22 End: 02/02/22 Due: 02/03/22

Study 40

Phase: N/A Priority: Normal
NCT ID: NCT00000039 Org: User:
Start: 02/10/22 End: 02/12/22 Due: 02/13/22

Study 50

Phase: N/A Priority: Normal
NCT ID: NCT00000049 Org: User:
Start: 02/20/22 End: 02/22/22 Due: 02/23/22

Study 60

Phase: N/A Priority: Normal
NCT ID: NCT00000059 Org: User:
Start: 03/02/22 End: 03/04/22 Due: 03/05/22

Study 70

Phase: N/A Priority: Normal
NCT ID: NCT00000069 Org: User:
Start: 03/12/22 End: 03/14/22 Due: 03/15/22

Study 80

Phase: N/A Priority: Normal
NCT ID: NCT00000079 Org: User:
Start: 03/22/22 End: 03/24/22 Due: 03/25/22

Study 90

Phase: N/A Priority: Normal
NCT ID: NCT00000089 Org: User:
Start: 04/01/22 End: 04/03/22 Due: 04/04/22

Study 100

Phase: N/A Priority: Normal
NCT ID: NCT00000099 Org: User:
Start: 04/11/22 End: 04/13/22 Due: 04/14/22

Study 110

Phase: N/A Priority: Normal
NCT ID: NCT00000109 Org: User:
Start: 04/21/22 End: 04/23/22 Due: 04/24/22

Agitation in Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00000179 Org: User:
Start: - End: - Due: -

A Study of the Effects of Advantage 24 on the Rectum

Phase: N/A Priority: Normal
NCT ID: NCT00000929 Org: User:
Start: - End: 07/31/99 Due: 07/31/00

A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease

Phase: N/A Priority: Normal
NCT ID: NCT00000729 Org: User:
Start: - End: 06/30/92 Due: 06/30/93

Calcium Supplements for Bone Health in Juvenile Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00000429 Org: User:
Start: 06/30/96 End: 05/31/01 Due: 05/31/02

Safety of Estrogens in Lupus: Hormone Replacement Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00000419 Org: User:
Start: 04/30/96 End: 08/31/02 Due: 08/31/03

Gepirone vs Placebo in Treatment of Cocaine Dependence - 3

Phase: N/A Priority: Normal
NCT ID: NCT00000189 Org: User:
Start: 01/31/90 End: 02/28/91 Due: 02/28/92

Infusion Laboratory: Protocol 3 (Risperidone) - 4

Phase: N/A Priority: Normal
NCT ID: NCT00000339 Org: User:
Start: 06/30/96 End: - Due: -

Piracetam for Treatment of Cocaine Addiction, Phase II - 4

Phase: N/A Priority: Normal
NCT ID: NCT00000199 Org: User:
Start: - End: - Due: -

Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)

Phase: N/A Priority: Normal
NCT ID: NCT00000499 Org: User:
Start: 09/30/80 End: 05/31/83 Due: 05/31/84

Prospective Evaluation of Radial Keratotomy (PERK) Study

Phase: N/A Priority: Normal
NCT ID: NCT00000129 Org: User:
Start: 04/30/81 End: 10/31/83 Due: 10/31/84

Novel Medications for Opiate Detoxification - 4

Phase: N/A Priority: Normal
NCT ID: NCT00000279 Org: User:
Start: 09/30/94 End: 08/31/99 Due: 08/31/00

A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3

Phase: N/A Priority: Normal
NCT ID: NCT00000779 Org: User:
Start: - End: 09/30/96 Due: 09/30/97

Tamoxifen Study

Phase: N/A Priority: Normal
NCT ID: NCT00000529 Org: User:
Start: 05/31/92 End: 11/30/95 Due: 11/30/96

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

Phase: N/A Priority: Normal
NCT ID: NCT00000829 Org: User:
Start: - End: 10/31/99 Due: 10/31/00